Pharma Turkey Dergisi Mayıs- Haziran 2017 Sayısı

Turkey’s largest drug exporter in the last 10 years
“Novartis”
Country President of Novartis Turkey Peter Catalino said; “Our long-term goal
is to grow together with Turkey and maintain our leading position in the sector
with more investment, more production and more R & D activities”
Operating in Turkey for more than 60 years, The Novartis
Group is among leading companies of the Turkish
pharmaceutical industry today with its Innovative Drugs,
Oncology, Sandoz and Alcon units and four production facilities.
Dr. Novartis has been serving as Country Head of Turkey for two
years. Peter Catalino shared his goals for the coming period,
evaluating the past year.
With the goal of growing together with Turkey in the upcoming
period, Country President of Novartis Turkey Peter Catalino
emphasizes that they are determined to be the pioneer of the
sector by investing more and maintaining their leadership
in exports, he said, “We have been in Turkey since 1955 as
Novartis Group. As Kurtkoy, Gebze 1, Gebze 2 and Tuzla, we
have 4 production facilities in Turkey. We are contributing to
the high technology production of Turkey with high value-added
medicines produced in these facilities. We support the vision of
the pharmaceutical industry and we are committed to continuing
our investments in R & D as well as production. We produce
our value-added molecules for patients in Turkey and in more
than 100 countries. Last year our total exports amounted to 150
million dollars. We exported 1.2 billion dollars to more than 100
countries in the last 10 years; Which makes us the largest drug
exporting group in Turkey. Thanks to the capacity and technical
infrastructure of our Kurtkoy production facility, we are able to
produce many products locally. We invested an additional $ 15
million to produce two high value products in 2016. Over the last
10 years we have invested over $ 240 million for our production
facilities. Our Gebze 1 facility is Turkey’s pharmaceutical export
champion. She has been at the Drug Exporters List every year
since 2010, and has been in the forefront for many years. This
product, which produces 45 molecules in solid, liquid and semisolid
form, is exported to more than 50 countries in Europe,
Latin America, Canada and Asia-Pacific. As a Novartis Group,
we are one of the leading pharmaceutical companies in R & D in
Turkey with over 100 ongoing clinical trials. In 2016 we invested
$ 39.4 million in clinical trials. Over the last 7 years we have
allocated more than $ 144 million to clinical trials in Turkey, so
we have provided support to Turkish doctors in global R & D
field. Today, as Novartis Group, we have close to 2,300 employees
in Turkey. We are investing in our employees and we are working
to create the best business environment for them.”
Pharma
May- June ‘17 21